Clinical Trials Logo

Hypertension clinical trials

View clinical trials related to Hypertension.

Filter by:
  • Recruiting  
  • Page 1 ·  Next »

NCT ID: NCT06330649 Recruiting - Hypertension Clinical Trials

The Acute Effect of and Energy Drink vs. Water Consumption on MAP, HR, and Energy Metabolism

Start date: January 1, 2024
Phase: N/A
Study type: Interventional

The objective of this protocol is to investigate the effect of consumption of a commercially available energy drink beverage on blood pressure, heart rate, and energy metabolism

NCT ID: NCT06319365 Recruiting - Hypertension Clinical Trials

Yoga on Women's Blood Pressure, Sexual Life, And Marital Compliance

Start date: March 1, 2023
Phase: N/A
Study type: Interventional

Introduction This study will examine the effects of a 12-week yoga program consisting of one-hour sessions three times a week on blood pressure, sexual life and marital adjustment among hypertensive women. Hypertension can adversely affect vascular health and affect marital relationships by contributing to sexual dysfunction. Method. The study will be a pre-post test randomized controlled study in accordance with CONSORT rules. Personal Information Form, Bloood pressure measurement, Arizona Sexual Experience Scale and Marital Adjustment Test will be used for data collection.

NCT ID: NCT06318390 Recruiting - Hypertension Clinical Trials

The Impact of KETO5 XOGenius Beverage on Markers of Physiological and Neurocognitive Health

Start date: August 1, 2023
Phase: N/A
Study type: Interventional

The primary objectives of this application are to 1) investigate the effect of increased daily consumption of the Keto5 XOGenius beverage on outcomes associated with elevated risk for various neurocognitive and pathophysiological conditions/diseases. And 2) to investigate the effect of daily consumption of the Keto5 XOGenius beverage on the following variables: waist circumference, body weight, and body mass index (BMI).

NCT ID: NCT06318377 Recruiting - Hypertension Clinical Trials

Peanuts and Neurocognitive / Cardiovascular Health in Black Individuals

Start date: September 1, 2022
Phase: N/A
Study type: Interventional

The overall research objective of this proposal is to determine the impact of increased daily peanut consumption on indices of neurocognitive and physiological health in BL individuals

NCT ID: NCT06317805 Recruiting - Clinical trials for Pulmonary Arterial Hypertension

Initial Triple Therapy Including Parenteral Treprostinil vs Initial Double Oral Therapy in PAH Group I Patients

TripleTRE
Start date: December 6, 2023
Phase: Phase 4
Study type: Interventional

TripleTRE investigates the effect of initial triple combination therapy (oral endothelin receptor antagonist (ERA) + oral phosphodiesterase tyüe-5 inhibitor (PDE-5i) + parenteral treprostinil) compared to double oral therapy (oral ERA + oral PDE-5i) in pulmonary arterial hypertension (PAH) patients (group I) with intermediate-high risk or patients with intermediate-low risk with severe hemodynamic impairment at baseline in a prospective, randomized, unblinded setting with scope of increasing evidence for optimization of therapy concepts in PAH. The effect of initial triple combination therapy vs initial double oral therapy (standard of care (SoC)) will be measured by primary endpoint: (non)response to the assigned treatment.

NCT ID: NCT06316544 Recruiting - Hypertension Clinical Trials

China Elderly Comorbidity Medical Database

CECMed
Start date: March 1, 2023
Phase:
Study type: Observational [Patient Registry]

The objective of this observational cohort study is to provide comprehensive evaluation and early warning for elderly patients with chronic diseases. The main question it aims to answer is: How to explore effective evaluation methods for diseases in elderly patients based on the coexistence of multiple diseases and high individual heterogeneity? How to explore the key indicators and influencing factors of adverse events in elderly patients.. Participants will be followed up at 1, 3, 6, 9, and 12 months to obtain adverse event information.

NCT ID: NCT06310148 Recruiting - Hypertension Clinical Trials

Evaluation of the Chronic Disease Co-Care Pilot Scheme

Start date: January 18, 2024
Phase: N/A
Study type: Interventional

The Chronic Disease Co-Care (CDCC) Pilot Scheme is initiated for early screening and management of people with hypertension (HT), pre-diabetes mellitus (pre-DM) and diabetes mellitus (DM) in Hong Kong. This study will evaluate the quality of care, feasibility, acceptability, effectiveness and cost-effectiveness of the Scheme. This is a 12-month cohort study among the District Health Centre (DHC) or DHC Express, healthcare providers, CDCC participants and a comparison group of 1,886 non-participants. All the person-in charge, 2 family doctors and 1 of each allied health provider from each DHC/DHC Express will be administered with the questionnaires on quality of care and costing. All CDCC participants will be included in subject characteristics, among which a convenience sample of 548 will complete a telephone survey on experience, enablement and satisfaction of the CDCC Pilot Scheme. The health outcomes of 1,886 CDCC participants and 1,886 non-participants will be compared for evaluation of effectiveness and cost-effectiveness. Participant characteristics, enablement, compliance to the standards of care, and costing of CDCC Pilot Scheme will be summarized using descriptive statistics. Differences in the proportion of patients meeting treatment targeted for HT, pre-DM and DM after 12 months will be compared by chi-squared test and logistic regressions. The incremental cost-effectiveness ratio will be evaluated by comparing with the World Health Organization (WHO) threshold. This study will inform future healthcare planning and policy for manpower and resource allocation.

NCT ID: NCT06309511 Recruiting - Hypertension Clinical Trials

Subendocardial Viability Ratio in Hypertension

SEVR-HT
Start date: October 1, 2022
Phase:
Study type: Observational

The aim of the research is to evaluate the Subendocardial Viability Ratio (SEVR) in hypertensive patients, using non-invasive arterial tonometry, and to establish the influencing factors and the possibility of predicting cardiovascular morbidity and mortality in arterial hypertension. The SEVR will be evaluated on all patients belonging to the Arterial Hypertension Centers undergoing non-invasive arterial tonometry. The SEVR is calculated on the morphology of the central pressure wave as the ratio between the DPTI (diastolic pressure-time index), i.e. the area between the carotid pressure curve and the ventricular pressure curve during the diastolic phase, and the SPTI ( systolic pressure-time index), i.e. the area under the carotid pressure curve during the systolic phase. The SEVR will be correlated with the anthropometric and pathology variables which will be collected in an appropriate database.

NCT ID: NCT06307574 Recruiting - Hypertension Clinical Trials

MedManage: Digital Technology to Support Adherence to Hypertension Medications

Start date: February 29, 2024
Phase: N/A
Study type: Interventional

The purpose of the MedManage study is to rigorously test the efficacy of a smartphone technology to help improve high blood pressure medication adherence among older adults with mild cognitive impairment (MCI) in a 16-week randomized controlled trial. A total of 100 older adults will be recruited. There will be two treatment arms, MedManage-S and MedManage-P with 50 participants in each arm. Participants randomized into the MEDManage-S intervention arm will use a smartphone application with medication reminders plus receive education with standardized information on hypertension and antihypertensive medications on the education portal. Participants in the MedManage-P group will use a smartphone to receive education with standardized information on hypertension and antihypertensive medications on an education portal. Both groups will complete baseline assessments followed by 4 weeks of medication adherence monitoring. At the end of the adherence monitoring period, participants will be randomized into one of the two treatment arms. Immediate outcomes on primary and secondary measures will be assessed 4 weeks after beginning of the intervention. Follow-up outcomes will be assessed 12 weeks after the beginning of the intervention.

NCT ID: NCT06302738 Recruiting - Hypertension Clinical Trials

Phenotypisation of Sleep Pattern in Hypertensive Patients With Non Dipper Pattern

INTO-DIP
Start date: May 4, 2023
Phase:
Study type: Observational

High blood pressure is the most common modifiable risk factor for cardiovascular diseases (CV). The large interindividual variability in clinical expression of the disease and response to treatment, however, makes the management of the hypertensive patient complex.Therefore, identifying phenotypes of hypertensive patients associated with a specific CV outcome or who tend to respond/not respond to treatment is of paramount importance for improving CV prevention. It has been shown that the phenotype of hypertensive patient with poor control of nighttime blood pressure values, especially when associated with a "non-dipper" profile, was associated with an increased risk of developing CV and cerebrovascular complications. The non-dipper profile and nocturnal hypertension are caused by several factors including excessive salt intake and dysautonomia. However, they are also inevitably influenced by sleep duration and the presence of sleep disorders: obstructive sleep apnea (OSA), but also insomnia and periodic movements of the lower limbs,such as those frequently seen in restless legs syndrome, are among the the main determinants related to altered nighttime pressure pattern. However, such disturbances are not systematically assessed during the performance of monitoring 24h pressor and their impact in the outcome of the hypertensive patient is unknown. The primary objective of this study is to phenotype non-dipper patients with or without nocturnal hypertension to determine the prevalence of sleep disorders such as sleep apnea syndrome, insomnia, and restless legs syndrome (RLS) (OSA diagnosed considering AHI>5 events/hour, insomnia and RLS according to ICSD 3 criteria) and correlate the presence of various sleep disorders with cardiac organ damage, vascular, and renal damage mediated by hypertension.